Tag - EDIT

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...